Toxicological Reviews

, Volume 25, Issue 3, pp 139–145

Lipid Rescue Resuscitation from Local Anaesthetic Cardiac Toxicity

Review Article

Abstract

Systemic local anaesthetic toxicity is a rare but potentially fatal complication of regional anaesthesia. This toxicity is due to inhibition of ionotropic and metabotropic cell signal systems and possibly mitochondrial metabolism. It is associated with CNS excitation and, in the extreme, refractory cardiac dysfunction and circulatory collapse. Infusion of lipid emulsion has been shown in animal models to reliably reverse otherwise intractable cardiac toxicity and the mechanism of lipid rescue is probably a combination of reduced tissue binding by re-established equilibrium in a plasma lipid phase and a beneficial energetic-metabolic effect. Recent case reports have suggested the clinical efficacy of lipid infusion by the recovery of patients from intractable cardiac arrest. Future areas of investigation will focus on improved treatment regimes and better understanding of the mechanism of lipid rescue, which might allow superior alternative therapies, or treatment of other toxic events. An educational website has been established to help disseminate information about lipid emulsion therapy and to serve as a medium for physicians to share experiences or thoughts on the method and local anaesthetic toxicity.

References

  1. 1.
    Weinberg GL. Current concepts in resuscitation of patients with local anesthetic cardiac toxicity. Reg Anesth Pain Med 2002; 27: 568–75PubMedGoogle Scholar
  2. 2.
    Albright GA. Cardiac arrest following regional anesthesia with etidocaine or bupivacaine. Anesthesiology 1979; 51: 285–7PubMedCrossRefGoogle Scholar
  3. 3.
    Mulroy MF. Systemic toxicity and cardiotoxicity from local anesthetics: incidence and preventive measures. Reg Anesth Pain Med 2002; 27: 556–61PubMedGoogle Scholar
  4. 4.
    Scott DB. Evaluation of clinical tolerance of local anaesthetic agents. Br J Anaesth 1975; 47 Suppl.: 328–31PubMedGoogle Scholar
  5. 5.
    Scott DB, Lee A, Fagan D, et al. Acute toxicity of ropivacaine compared with that of bupivacaine. Anesth Analg 1989; 69: 563–9PubMedGoogle Scholar
  6. 6.
    Morishima HO, Pedersen H, Finster M, et al. Bupivacaine toxicity in pregnant and nonpregnant ewes. Anesthesiology 1985; 63: 134–9PubMedCrossRefGoogle Scholar
  7. 7.
    Groban L, Deal DD, Vernon JC, et al. Cardiac resuscitation after incremental overdosage with lidocaine, bupivacaine, levobupivacaine, and ropivacaine in anesthetized dogs. Anesth Analg 2001; 92: 37–43PubMedCrossRefGoogle Scholar
  8. 8.
    Clarkson CW, Hondeghem LM. Mechanism for bupivacaine depression of cardiac conduction: fast block of sodium channels during the action potential with slow recovery from block during diastole. Anesthesiology 1985; 62: 396–405PubMedCrossRefGoogle Scholar
  9. 9.
    Mio Y, Fukuda N, Kusakari Y, et al. Comparative effects of bupivacaine and ropivacaine on intracellular calcium transients and tension in ferret ventricular muscle. Anesthesiology 2004; 101: 888–94PubMedCrossRefGoogle Scholar
  10. 10.
    Lynch C. Depression of myocardial contractility in vitro by bupivacaine, etidocaine, and lidocaine. Anesth Analg 1986; 65: 551–9PubMedGoogle Scholar
  11. 11.
    Nietgen GW, Chan CK, Durieux ME. Inhibition of lysophosphatidate signaling by lidocaine and bupivacaine. Anesthesiology 1997; 86: 1112–9PubMedCrossRefGoogle Scholar
  12. 12.
    Butterworth JF, Brownlow RC, Leith JP, et al. Bupivacaine inhibits cyclic-3′,5′-adenosine monophosphate production: a possible contributing factor to cardiovascular toxicity. Anesthesiology 1993; 79: 88–95PubMedCrossRefGoogle Scholar
  13. 13.
    Courtney KR, Kendig JJ. Bupivacaine is an effective potassium channel blocker in heart. Biochim Biophys Acta 1988; 939: 163–6PubMedCrossRefGoogle Scholar
  14. 14.
    Dabadie P, Bendriss P, Erny P, et al. Uncoupling effects of local anesthetics on rat liver mitochondria. FEBS Lett 1987; 226: 77–82PubMedCrossRefGoogle Scholar
  15. 15.
    Sztark F, Malgat M, Dabadie P, et al. Comparison of the effects of bupivacaine and ropivacaine on heart cell mitochondrial bioenergetics. Anesthesiology 1998; 88: 1340–9PubMedCrossRefGoogle Scholar
  16. 16.
    Weinberg GL, Palmer JW, VadeBoncouer TR, et al. Bupivacaine inhibits acylcarnitine exchange in cardiac mitochondria. Anesthesiology 2000; 92: 523–8PubMedCrossRefGoogle Scholar
  17. 17.
    Rosen MA, Thigpen JW, Shnider SM, et al. Bupivacaine-induced cardiotoxicity in hypoxic and acidotic sheep. Anesth Analg 1985; 64: 1089–96PubMedCrossRefGoogle Scholar
  18. 18.
    Weinberg GL, Laurito CE, Geldner P, et al. Malignant ventricular dysrhythmias in a patient with isovaleric acidemia receiving general and local anesthesia for suction lipectomy. J Clin Anesth 1997; 9: 668–70PubMedCrossRefGoogle Scholar
  19. 19.
    Indiveri C, Tonazzi A, Prezioso G, et al. Kinetic characterization of the reconstituted carnitine carrier from rat liver mitochondria. Biochim Biophys Acta 1991; 1065: 231–8PubMedCrossRefGoogle Scholar
  20. 20.
    Rubio-Gozalbo ME, Vos P, Forget PP, et al. Carnitine-acylcarnitine translocase deficiency: case report and review of the literature. Acta Paediatr 2003; 92: 501–4PubMedCrossRefGoogle Scholar
  21. 21.
    Weinberg GL, VadeBoncouer T, Ramaraju GA, et al. Pretreatment or resuscitation with a lipid infusion shifts the dose-response to bupivacaine-induced asystole in rats. Anesthesiology 1998; 88: 1071–5PubMedCrossRefGoogle Scholar
  22. 22.
    Weinberg G, Ripper R, Feinstein DL, et al. Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med 2003; 28: 198–202PubMedGoogle Scholar
  23. 23.
    Groban L, Butterworth J. Lipid reversal of bupivacaine toxicity: has the silver bullet been identified? Reg Anesth Pain Med 2003; 28: 167–9PubMedGoogle Scholar
  24. 24.
    Weinberg GL, Ripper R, Murphy P, et al. Lipid infusion accelerates removal of bupivacaine and recovery from bupivacaine toxicity in the isolated rat heart. Reg Anesth Pain Med 2006; 31: 296–303PubMedGoogle Scholar
  25. 25.
    Collins-Nakai RL, Noseworthy D, Lopaschuk GD. Epinephrine increases ATP production in hearts by preferentially increasing glucose metabolism. Am J Physiol 1994; 267: H1862–71PubMedGoogle Scholar
  26. 26.
    Eledjam JJ, de La Coussaye JE, Brugada J, et al. In vitro study on mechanisms of bupivacaine-induced depression of myocardial contractility. Anesth Analg 1989; 69: 732–5PubMedCrossRefGoogle Scholar
  27. 27.
    Van de Velde M, Wouters PF, Rolf N, et al. Long-chain triglycerides improve recovery from myocardial stunning in conscious dogs. Cardiovasc Res 1996; 32: 1008–15PubMedCrossRefGoogle Scholar
  28. 28.
    Van de Velde M, DeWolff M, Leather HA, et al. Effects of lipids on the functional and metabolic recovery from global myocardial stunning in isolated rabbit hearts. Cardiovasc Res 2000; 48: 129–37PubMedCrossRefGoogle Scholar
  29. 29.
    Stehr SN, Ziegler J, Pexa A, et al. Lipid effects on myocardial function in L-bupivacaine induced toxicity in the isolated rat heart [abstract]. Reg Anesth Pain Med 2005; 30: 5CrossRefGoogle Scholar
  30. 30.
    Cho HS, Lee JJ, Chung IS, et al. Insulin reverses bupivacaine-induced cardiac depression in dogs. Anesth Analg 2000; 91: 1096–102PubMedGoogle Scholar
  31. 31.
    Kim JT, Jung CW, Lee KH. The effect of insulin on the resuscitation of bupivacaine-induced severe cardiovascular toxicity in dogs. Anesth Analg 2004; 99: 728–33PubMedCrossRefGoogle Scholar
  32. 32.
    Weinberg G, VadeBoncouer T. Improved energetics may explain the favorable effect of insulin infusion on bupivacaine cardiotoxicity. Anesth Analg 2001; 92: 1075–6PubMedCrossRefGoogle Scholar
  33. 33.
    Renehan EM, Enneking FK, Varshney M, et al. Scavenging nanoparticles: an emerging treatment for local anesthetic toxicity. Reg Anesth Pain Med 2005; 30: 380–4PubMedGoogle Scholar
  34. 34.
    Picard J, Meek T. A response to ‘lipid emulsion to treat bupivacaine toxicity’. Anaesthesia 2005; 60: 1158PubMedCrossRefGoogle Scholar
  35. 35.
    Rosenblatt MA, Abel M, Fischer GW, et al. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology 2006; 105: 217–8PubMedCrossRefGoogle Scholar
  36. 36.
    Litz RJ, Popp M, Stehr SN, et al. Successful resuscitation of a patient with ropivacaine-induced asystole after axillary plexus block using lipid infusion. Anaesthesia 2006; 61: 800–1PubMedCrossRefGoogle Scholar
  37. 37.
    Ohmura S, Ohta T, Yamamoto K, et al. A comparison of the effects of propofol and sevoflurane on the systemic toxicity of intravenous bupivacaine in rats. Anesth Analg 1999; 88: 155–9PubMedGoogle Scholar
  38. 38.
    Barson AJ, Chistwick ML, Doig CM. Fat embolism in infancy after intravenous fat infusions. Arch Dis Child 1978; 53: 218–23PubMedCrossRefGoogle Scholar
  39. 39.
    Corcoran W, Beck JM, Gerancher J, et al. Local anesthetic-induced cardiac toxicity: a survey of contemporary practice strategies among academic anesthesiology departments [abstract]. Anesth Analg 2006; 102: S–316Google Scholar
  40. 40.
    Cave G, Harvey M, Castle C. The role of fat emulsion therapy in a rodent model of propranolol toxicity: a preliminary study. Med Toxicol 2006; 2: 4–7CrossRefGoogle Scholar
  41. 41.
    Minton N, Goode A, Henry J. The effect of a lipid suspension on amitryptiline disposition. Arch Toxicol 1987; 60: 467–9PubMedCrossRefGoogle Scholar
  42. 42.
    LipidRescue™: resuscitation for local anesthetic toxicity [online]. Available from URL: http://www.lipidrescue.org [Accessed 2006 Oct 5]

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.University of Illinois College of MedicineChicagoUSA
  2. 2.Department of Anesthesiology, M/C515University of Illinois HospitalChicagoUSA

Personalised recommendations